TP53 and myelodysplastic syndrome: APR-246 has activity in cells without detectable TP53 expression and in WT TP53 cells by inducing heightened oxidative stress resulting in cell apoptosis [140] Due to a synergistic effect with azacytidine (AZA) in preclinical AML models, Eprenetapopt is being tested in a phase 1b/2 study in the treatment of naïve high risk myelodysplastic syndrome (HR-MDS) and oligoblastic (20–30% blasts) AML patients.